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AbsTrACT
Introduction There is conflicting evidence regarding 
the benefits of percutaneous coronary intervention (Pci) 
in patients with grey zone fractional flow reserve (gZFFr 
artery) values (0.75–0.80). The prevalence of ischaemia 
is unknown. We wished to define the prevalence of 
ischaemia in gZFFr artery and assess whether Pci is 
superior to optimal medical therapy (OMT) for angina 
control.
Methods We enrolled 104 patients with angina 
with 1:1 randomisation to Pci or OMT. The artery was 
interrogated with a Doppler flow/pressure wire. Patients 
underwent Magnetic resonance imaging (Mri) with 
follow- up at 3 and 12 months. The primary outcome 
was angina status at 3 months using the seattle angina 
Questionnaire (saQ).
results 104 patients (age 60±9 years), 79 (76%) 
males and 79 (76%) left anterior Descending (laD) 
stenoses were randomised. coronary physiology and saQ 
were similar. Of 98 patients with stress perfusion Mri 
data, 17 (17%) had abnormal perfusion (≥2 segments 
with ≥25% ischaemia or ≥1 segment with ≥50% 
ischaemia) in the target gZFFr artery. Of 89 patients with 
invasive physiology data, 26 (28%) had coronary flow 
velocity reserve <2.0 in the target gZFFr artery. after 3 
months of follow- up, compared with patients treated 
with OMT only, patients treated by Pci and OMT had 
greater improvements in saQ angina frequency (21 (28) 
vs 10 (23); p=0.026) and quality of life (24 (26) vs 11 
(24); p=0.008) though these differences were no longer 
significant at 12 months.
Conclusions non- invasive evidence of major ischaemia 
is uncommon in patients with gZFFr artery. compared 
with OMT alone, patients randomised to undergo Pci 
reported improved symptoms after 3 months but these 
differences were no longer significant after 12 months.
Trial registration number ncT02425969.
InTroduCTIon
As percutaneous coronary intervention (PCI) has 
evolved, it has become increasingly important to 
accurately identify those patients most likely to 
derive symptomatic benefit. The use of fractional 
flow reserve (FFR) to guide decision making has 
been given a class I, level of evidence A indica-
tion by the European Society of Cardiology.1 The 
original clinical validation used a combination of 
treadmill exercise stress testing, myocardial perfu-
sion imaging with thallium and dobutamine stress 
echo (DSE) determined that the threshold whereby 
a coronary stenosis was highly likely to be capable 
of inducing significant myocardial ischaemia was 
≤0.75.2 Using this cut- off value, a high concor-
dance between FFR and stress perfusion MRI has 
been confirmed.3 4 The clinical utility of this FFR 
cut- off value was established in the DEFER study 
in which it was shown that it was safe to defer PCI 
in lesions with an FFR ≥0.75.5 In order to improve 
sensitivity and minimise the risk of undertreatment, 
an FFR cut- off value of ≤0.80 was adopted in the 
FAME and FAME-2 trials6 7 both of which demon-
strated improved outcomes with FFR guidance.8 
Consequently, there is an FFR grey- zone (GZFFR) 
between 0.75 and 0.80 within which the need to 
perform revascularisation is less clear.1 Importantly, 
a meta- analysis of pooled FFR and outcome data 
in medically treated and revascularised patients 
demonstrated that the optimal FFR cut- off value 
with regard to major adverse cardiac events 
(MACE) defined as death, MI and revascularisation 
was <0.75 on a study level analysis and 0.67 on a 
patient level analysis.9
To date, most studies in patients with GZFFR values 
have been retrospective, small, non- randomised and 
limited by selection bias with conflicting outcomes 
at follow- up.10–15 One retrospective observa-
tional study by Adjedj et al reported no significant 
difference in MACE for GZFFR patients treated 
with PCI plus optimal medical therapy (OMT) or 
OMT alone after 5 years of follow- up, 11.2% vs 
13.9%, p=0.3.16 These findings were confirmed 
in the GZFFR cohort of the IRIS- FFR Registry with 
MACE rates of 8.1% in the deferred group vs 8.4% 
in the PCI group at a median follow- up of 2.9 years, 
p=0.79.17 This randomised trial was designed to 
assess whether PCI in patients with GZFFR values 
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Figure 1 GZFFR flowchart. ‘Screening FFR’ used any pressure wire 
system for basic FFR assessment without flow indices. All subsequent 
measurements involved the Combowire device to assess indices of 
pressure, flow and resistance. FFR, fractional flow reserve; GzFFR, grey 
zone; OMT, optimal medical therapy; PCI, percutaneous coronary 
intervention and optimal medical therapy group; Pd/Pa, resting pressure 
gradient; QCA, quantitative coronary angiography; STEMI, ST elevation 
myocardial infarction.
would be associated with improvements in symptoms and 
whether any such improvement could be predicted by preproce-
dural myocardial perfusion imaging or by invasive physiological 
indices of stenosis severity other than FFR itself.
MeThods
The GZFFR study enrolled patients from the West of Scotland 
Regional Heart and Lung Centre in the Golden Jubilee National 
Hospital (GJNH), Glasgow, UK. Ethical approval was obtained 
from the West of Scotland Research Ethics Committee. There 
was no formal Patient and Public Involvement in the design or 
conduct of this trial.
Inclusion and exclusion criteria
We recruited consecutive consenting patients with a clinical 
indication for a pressure wire based diagnostic evaluation of 
an intermediate coronary lesion (30%–80% diameter stenosis 
by visual assessment) who had GZFFR values between 0.75 and 
0.82. Patients were eligible if they had either stable angina or 
residual non- culprit disease after non- ST elevation myocar-
dial infarction or ST elevation myocardial infarction (STEMI) 
following treatment of the culprit vessel. In patients returning 
for planned pressure wire studies following culprit vessel 
PCI, a minimum interval of 2 weeks from the index event was 
required and symptoms had to be stable for ≥3 days. Patients 
with excessive tortuosity, calcification or left main disease with 
≥50% diameter stenosis were excluded (figure 1). Patients were 
ineligible for randomisation in the event of residual untreated 
obstructive coronary disease in another vessel ≥2 mm in calibre.
design
Between May 2015 and October 2016, we recruited 104 patients 
who were randomised 1:1 to PCI with OMT (PCI) or OMT 
alone using sealed envelopes provided by the Robertson Centre 
for Biostatistics, University of Glasgow. They were stratified by 
gender, diabetic status and 65 years of age cut- off. The primary 
outcome measure was angina status assessed using the Seattle 
Angina Questionnaire (SAQ). Patients completed their first SAQ 
immediately following baseline coronary angiography and inva-
sive physiology studies except for patients who underwent PCI 
of another non GZFFR vessel at the time of recruitment where 
the SAQ was completed at least 4 weeks after the initial PCI. At 
3 months following randomisation, the second SAQ was admin-
istered over the telephone by a research nurse who was blinded 
to treatment group and all other data. Recruitment was stopped 
when 104 patients had undergone successful randomisation 
following discussion with the trial biostatistician as our loss to 
follow- up rate was lower than expected.
non-invasive ischaemia assessment
This was performed using stress perfusion MRI. Standard tech-
niques were employed with three short axis cuts during rest 
and adenosine stress phases and administration of a bolus of 
0.05 mmol/kg gadolinium. Study participants, clinicians and clin-
ical research nurses were all blinded to the perfusion MRI. All 
images were analysed on a Medis Suite 2.1.12.2 Medis Medical 
Imaging Systems (Leiden, The Netherlands) workstation by 
two cardiologists with Level 3 accreditation with the European 
Association of Cardiovascular Imaging (CB and DC). Both data-
sets were then adjudicated in the event of discordance a third 
observer (SW). Images were assessed according to 16 segment 
American Heart Association analysis to define the extent of 
ischaemia. The definition of significant reversible ischaemia was 
≥2 segments with ≥25% ischaemia or ≥1 segment with ≥50% 
ischaemia similar to recent studies.18 Patients unable to undergo 
MRI studies were assessed using DSE.
Medical therapy and titration of antianginal drugs
All of the participants received OMT in line with contempo-
rary guidelines with titration of antianginals as clinically appro-
priate19 though this was patient driven and not performed 
according to a preset protocol. Patients with persistent or recur-
rent angina postrandomisation underwent titration of medica-
tions supervised by the clinical research staff. When a treatment 
change was indicated by ongoing anginal symptoms, the patient 
was contacted in person or by telephone followed up by email 
or letter and advised to attend their GP in order to have their 
prescription modified accordingly. All patients were directed to 
follow- up with the research team within 2 weeks to assess the 
clinical response and to notify the research team in the event of 
either a failure to control angina, hospitalisation or other clinical 
event. Beyond that, patients had email and phone access to a 
consultant cardiologist for purposes of management of poorly 
controlled symptoms. Patients could cross over from the OMT 
group to the PCI group at any time during follow- up though 
they were encouraged to persist with the assigned treatment 
group for 3 months if feasible.
Coronary physiology studies
Following identification of a vessel with a GZFFR value using 
a conventional pressure wire, a Phillips Volcano Combowire 
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Table 1 Risk factors according to treatment strategy and symptom 
status, previous cardiac history and mode of presentation at time of 
recruitment
Variable
oMT
n=52
PCI
n=52
Age 61 (SD 9.0) 60 (SD 8.0)
Male 39 (75%) 40 (76.9%)
Female 13 (25%) 12 (23.1%)
Current smoker 13 (25%) 21 (40.3%)
Previous smoking 13 (25%) 11 (21.1%)
hTn 44 (84.6%) 31 (59.6%)
Hyperlipidaemia 31 (59.6%) 38 (73.1%)
T2DM 10 (19.2%) 10 (19.2%)
IDDM 2 (3.8%) 2 (3.8%)
FHX CAD 38 (73.1%) 33 (63.5%)
PVD 4 (7.7%) 6 (11.5%)
Cerebrovascular disease 4 (7.7%) 4 (7.7%)
Significant differences indicated in bold, p value for HTN=0.004.
FHX CAD, family history coronary artery disease; HTN, hypertension; IDDM, insulin 
dependent diabetes; OMT, optimal medical therapy group; PCI, percutaneous 
coronary intervention group; PVD, peripheral vascular disease; T2DM, type 2 
diabetes mellitus.
Table 2 Table 1 Clinical features according to treatment strategy
Variable
oMT
(n=52)
PCI
(n=52)
NYHA Class
  1 31 (59.6%) 39 (75%)
  2 13 (25%) 9 (17.3%)
  3 4 (7.6%) 2 (3.8%)
  4 3 (5.7%) 2 (3.8%)
CCS Class*
  1 11 (21.2%) 14 (26.9%)
  2 30 (57.7%) 30 (57.7%)
  3 4 (7.7%) 4 (7.7%)
  4 7 (13.5%) 4 (7.7%)
Previous PCI 28 (53.8%) 36 (69.2%)
Previous MI 21 (40.4%) 31 (59.6%)
Presentation
Stable angina 32 (61.5%) 21 (40.4%)
Non- culprit NSTEMI 12 (23.1%) 17 (32.7%)
Unstable angina 3 (5.8%) 3 (5.8%)
Non- culprit STEMI 5 (9.6%) 11 (21.2%)
CCS Class may not be indicative of anginal class as per Seattle Angina 
Questionnaire in the setting of non- culprit disease where scores were calculated at 
a minimum of 4 weeks post initial PCI in order to ensure scores were reflective of 
angina from the GZFFR vessel under study.
CCS, Canadian Cardiovascular Society; NSTEMI, non- ST elevation myocardial 
infarction; OMT, optimal medical therapy group; PCI, percutaneous coronary 
intervention; STEMI, ST elevation myocardial infarction.
was equalised and introduced into the distal third of the target 
coronary artery. An intracoronary bolus of 200 µg of isosorbide 
dinitrate was administered followed by intravenous infusion of 
adenosine at 140 mcg/kg/min. After data acquisition, the wire 
was withdrawn to check for pressure drift. Drift ≥0.03 was 
considered unacceptable necessitating repeated measurements. 
All data were anonymised and analysed with Combomap V.1.9 
software. Each recording was reviewed with attention to flow 
signal quality and pressure signals for pressure damping with 
classification of results according to published cut- offs.20
Coronary angiography and PCI
Coronary angiography was performed as per standard practice 
in the in Golden Jubilee National Hospital (GE Innova 2121 and 
2100). Quantitative coronary analysis was performed on a work-
station using computer- assisted planimetry QAngio XA 3D 1.0 
(MEDIS, Leiden). An APPROACH Score was calculated for each 
lesion in order to evaluate the volume of myocardium subtended 
by the vessel of interest.21 PCI was performed according to inter-
national guidelines.1
statistics and sample size calculation
The study design and final analysis involved an experienced 
biostatistician (JDM). We required 108 subjects to provide 90% 
power at a multiple testing adjusted 5% level of significance to 
detect a clinically relevant difference of 10 points for each of the 
five components of the SAQ between the OMT and PCI groups 
assuming a within group SD of 18 points as per similar studies.22 
We expected loss to follow- up of 10%. T- tests or χ² tests were 
used where appropriate. A posthoc analysis using ANCOVA was 
performed using Hochberg’s FWER procedure. We explored the 
ability of coronary flow velocity reserve (CFVR), Hyperaemic 
Stenosis Resistance Index (HSR) and hyperaemic microvascular 
resistance (HMR) to predict the presence of ischaemia on stress 
perfusion MRI using ROC curves using SPSS statistics package 
V.21.0. Armonk, New York, USA: IBM.
results
During the period of this study, we performed FFR assessment 
in 1026 patients of whom 127 (12.4%) had values of 0.75–0.82 
inclusive. All of these patients were invited to participate in the 
trial and 108 agreed. Subsequently, three patients withdrew 
consent and one patient had non- GZFFR physiology at the time of 
planned PCI and was excluded leaving 104 randomised patients 
(table 1). See table 2 for details regarding clinical presentation. 
One patient randomised to PCI had severe myocardial bridging 
adjacent to the target stenosis potentially compromising the safe 
performance of PCI and was managed medically. One patient 
randomised to PCI travelled abroad with a resultant delay in the 
patient receiving their assigned treatment. This patient sustained 
a spontaneous STEMI in the territory of the target artery at 40 
days postrandomisation and underwent emergency PCI. All 
other patients received their allocated treatment (figure 2) and all 
results are reported by intention to treat. The mean (SD) number 
of antianginal drugs in each group at 3 months follow- up was 1.5 
(0.7) with OMT only vs 1.3 (0.8) with PCI plus OMT; p=0.15 
(online supplementary eTable 1). Drug eluting stents were used 
in all patients.
Baseline quantitative coronary angiography
The coronary arteries with GZFFR values were the left ante-
rior descending in 79 patients (76%), the right in 14 patients 
(14%) and the left circumflex in 8 patients (8%). See online 
supplementary eTable 2 for further segmental breakdown. There 
was no significant difference between groups in terms of any 
baseline QCA variables (table 3).
Invasive coronary physiology
In addition to the qualifying FFR measurement, 89/93 patients 
had additional measurements of CFVR that were of sufficient 
quality for analysis. There were no significant differences 
between the groups at baseline with mean (SD) FFR value of 0.78 
(0.02). While all patients had GZFFR physiology confirmed on 
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Figure 2 Consort flow diagram for the GZFFR trial. *One patient died 
at 65 days postrandomisation following a witnessed fall with traumatic 
intracranial haemorrhage, another died at 51 days postrandomisation 
from metastatic lung cancer diagnosed during the MRI performed as 
part of the study and the third died of pulmonary emboli post resection 
of a chronic benign meningioma at 84 days postrandomisation. 
Combowire, combined pressure and Doppler flow wire; FFR, fractional 
flow reserve; GZFFR, grey zone; OMT, optimal medical therapy; PCI, 
percutaneous coronary intervention and optimal medical therapy group.
Table 3 Quantitative coronary angiographic data according to 
treatment strategy
Variable oMT (n=52) PCI (n=52)
Diameter stenosis (%) 44 (8) 45 (10)
  Area stenosis (%) 69 (8) 69 (10)
Lesion length (mm) 10 (4) 10 (4)
APPROACH Score (%) 32 (9) 32 (8)
OMT, optimal medical therapy group; PCI, percutaneous coronary intervention 
group.
Table 4 Physiology for all patients with Combowire data including 
post- PCI Combowire results pressure following Core Laboratory 
analysis (n=89/93), flow and resistance data for all randomised 
patients with Combowire data according to treatment group
baseline invasive physiology for entire cohort
n Minimum Maximum Mean (sd)
FFR 89 0.75 0.82 0.78 (0.02)
HMR 89 0.9 6.9 2.10 (0.84)
HSR 89 0.15 2.00 0.52 (0.25)
CFVR 89 1.3 5.0 2.41 (0.75)
by randomised group
 n Mean sd
FFR OMT 38 0.78 0.02
PCI 51 0.78 0.02
HMR OMT 38 2.21 0.74
PCI 51 2.01 0.91
HSR OMT 38 0.55 0.21
PCI 51 0.50 0.27
CFVR OMT 38 2.35 0.72
PCI 51 2.45 0.77
Invasive physiology pre- PCI and post- PCI
 Pre- PCI Post- PCI n P value
FFR 0.77 (0.02) 0.90 (0.06) 41 0.001
HMR 2.07 (0.98) 2.31 (0.95) 41 0.02
HSR 0.51 (0.29) 0.20 (0.18) 40 0.001
CFVR 2.34 (0.73) 2.28 (0.69) 40 0.548
CFVR, coronary flow velocity reserve; FFR, fractional flow reserve; HMR, hyperaemic 
microvascular resistance; HSR, Hyperaemic Stenosis Resistance Index; N, total 
number of patients; OMT, optimal medical therapy group; PCI, percutaneous 
coronary intervention with medical therapy group.
their first pressure wire assessment at enrolment, before Doppler 
flow interrogation, there was less Doppler flow data available 
in the OMT versus PCI group (n=38 vs 51, respectively) as 
there was a second opportunity to acquire flow data in patients 
reattending for PCI with protocol mandated repeat physiology 
pre- PCI. Potentially ischaemic values of CFVR (<2.0) and HSR 
(≥0.8 mm Hg/cm/s) were observed in 26/89 (29%) and 7/89 
(8%) of patients, respectively. HMR was elevated (>2.3 mm Hg/
cm/s) in 27/89 (30%) of cases (online supplementary eFigure 1). 
A total of 42/52 (78.9%) of patients undergoing PCI had both 
pre- PCI and post- PCI invasive physiology assessment. FFR pre- 
PCI was 0.77 (0.02) compared with 0.90 (0.06) post- PCI; mean 
delta 0.12 (95%CI 0.11 to 0.15), p=0.0001 (table 4).
Primary outcome measure (SAQ scores)
Of the 104 randomised patients, 100 pairs of SAQ data were 
available (96% of the randomised cohort) and three patients in 
the OMT only group died due to non- cardiac causes before the 
primary endpoint assessment at 3 months (figure 2). A fourth 
patient, also in the OMT only group, was lost to follow- up but 
was confirmed to be alive and free of angina 1 year postrandomi-
sation via their family doctor. The within group mean change in 
the SAQ domain of angina frequency from baseline to 3 months 
was 10 (23) with OMT alone vs 21 (28) with PCI plus OMT; 
p=0.04. The within group mean change in the SAQ domain of 
quality of life (QOL) from baseline to 3 months was 11 (24) 
with OMT alone vs 24 (26) with PCI plus OMT; p=0.01. There 
were no significant differences in the SAQ domains of treatment 
satisfaction, physical limitation or angina stability (table 5 and 
online supplementary eFigure 2). The within group mean change 
for the SAQ summary score was 17 (18) with OMT alone vs 25 
(21) with PCI plus OMT, p=0.04. Posthoc analysis of covariance 
(ANCOVA) incorporating baseline SAQ scores and using Hoch-
berg’s FWER error rate adjusted p values confirmed a statisti-
cally significant difference between OMT and PCI plus OMT 
for Anginal Frequency (p=0.04) and QOL (p=0.02). At base-
line, there was no between group difference for ‘Freedom from 
Angina’ (Angina Frequency score=100) but a significant differ-
ence between groups was observed at 3 months: 20/48 (41.7%) 
with OMT alone vs 34/52 (65.4%) with PCI plus OMT, p=0.02.
non-invasive evidence of ischaemia
A total of 98 patients had perfusion MRI data (online supplemen-
tary eTable 4). Of these, 74 (76%) had no detectable ischaemia 
in the territory of the GZFFR vessel (online supplementary eTable 
5). Five patients were unable to undergo perfusion MRI and had 
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Figure 3 This patient had a moderately severe mid left circumflex 
lesion with GZFFR physiology with reduced CFVR of 1.5 pre- PCI 
which improved to a CFVR of 4 post- PCI. The stenosis resistance HSR 
reduced following PCI with improved FFR. GZFFR coronary lesion in mid 
circumflex indicated by blue arrow before PCI (upper panel) and after 
PCI with coronary physiology data in the left panel. CFVR, coronary flow 
velocity reserve; FFR, fractional flow reserve; GZFFR, grey zone; HSR, 
Hyperaemic Stenosis Resistance Index.
Table 5 Mean change in SAQ scores from baseline to 3 months
sAQ 
parameter Group n Mean sd
95% CI of the 
difference P value
Summary Score OMT 48 17 18 +1.5 to +18 0.04
PCI 52 25 21
Physical 
limitation
OMT 48 11 23 −4 to +15 0.28
PCI 52 16 26
Anginal stability OMT 48 −3 34 −14 to +12 0.91
PCI 52 −3 33
Anginal 
frequency
OMT 48 10 24 +1 to +21 0.04
PCI 52 21 28
Treatment 
satisfaction
OMT 48 −4 20 −1 to 12 0.10
PCI 52 2 13
Quality of life OMT 48 11 24 +3 to +23 0.01
PCI 52 24 26
A higher value indicates improved clinical status (see online supplementary eTable 
3 for baseline values).
OMT, optimal medical therapy group; PCI, percutaneous coronary intervention with 
medical therapy group; SAQ, Seattle Angina Questionnaire score.
DSE instead. None of this group had detectable ischaemia in the 
territory of the GZFFR vessel. There was no significant between 
group difference in the incidence of ischaemia on non- invasive 
testing at baseline (p=0.41) (online supplementary eTable 6). 
Postprocedural MRI data were available in 41/51 patients who 
were randomised to undergo PCI. Of these, 3/41 (7.3%) still had 
detectable ischaemia in the GZFFR territory. Diagnostic accuracy 
of CFVR, HSR and HMR for predicting major ischaemia on 
MRI pre randomisation was assessed. HSR was the most predic-
tive at 0.609, (95% CI 0.442 to 0.783) (online supplementary 
eFigure 3).
secondary outcomes at 3 months
This study was not powered to detect a difference in hard clin-
ical endpoints. All- cause mortality at 3 months was 3/52 (5.7%) 
in OMT group (all confirmed non- cardiac deaths) vs 0/52 (0%) 
in PCI group.
12-month follow-up
After 12 months, 89/100 patients completed another SAQ 
(online supplementary eTable 7). The within group mean change 
in the SAQ domain scores from baseline to 12 months remained 
numerically higher in patients treated by PCI plus OMT versus 
OMT alone but these differences were no longer statistically 
significant, possibly due to a loss of power and/or restenosis.
dIsCussIon
Prior studies do not indicate that hard clinical events are likely 
to be reduced by PCI in patients with GZFFR coronary physi-
ology.16 17 As such, most of the justification for PCI in this group 
of patients must be based on an anticipated improvement in 
symptoms and quality of life. In this single- centre prospective 
randomised trial of OMT versus PCI plus OMT in patients with 
angina and GZFFR values, patients assigned to PCI reported a 
significant improvement in symptoms and quality of life as 
assessed by the SAQ. Freedom from angina was also significantly 
more frequent in the PCI group. Non- invasive evidence of isch-
aemia on stress perfusion MRI was only identified in around 1/4 
of these patients with GZFFR although full quantitative perfusion 
analysis was not performed. Combined pressure and Doppler 
flow wire technology in its current form is difficult to use but 
the concept of using flow, pressure and resistance to determine 
the potential benefit of revascularisation remains attractive 
(figure 3).23 Indeed, HSR was the best invasive physiological 
index for predicting the presence of perfusion abnormalities 
with the relatively modest agreement most probably due to the 
low prevalence of ischaemia in this cohort (online supplemen-
tary eFigure 3).
Prior to this study, we had anticipated that a large proportion 
of patients with angina, coronary disease and GZFFR physiology 
considered for treatment with PCI could achieve equivalent 
symptoms control with medical management only. However, 
as a group, the patients randomised to PCI demonstrated supe-
rior symptom control and quality of life after 3 months and this 
treatment effect was still apparent after 12 months follow- up. 
Longer follow- up in a larger scale study will be important to 
further clarify the roles of medical management and PCI in this 
group.
Limitations
The major limitation of this study is that we did not employ 
a placebo group and, as the patients in this study were aware 
of their allocated treatment, we cannot out rule a placebo 
effect. Reassuringly, the magnitude of the improvement in SAQ 
scores with PCI exceeded that reported in the placebo arm of 
the ORBITA trial despite the fact that significantly less medical 
therapy was administered to our PCI group than in ORBITA (1.3 
vs 2.9 anti- anginal drugs; online supplementary eTable 8). In our 
study, 94% of patients had an FFR ≤0.80 compared with only 
71% in ORBITA and this may explain the greater improvement 
observed with PCI.24
ConCLusIon
We have performed a prospective randomised controlled trial 
of open- label PCI plus medical therapy versus medical therapy 
only in patients with angina, coronary disease and GZFFR values. 
Despite a relatively low incidence of ischaemia on non- invasive 
testing, patients treated by PCI reported fewer symptoms and 
improved quality of life, some of which may have been due to a 
placebo effect.
Twitter Barry hennigan @barryhennigan, Kenneth Mangion @kenneth_mangion 
and Thomas Joseph Ford @tomjford
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Key questions
What is already known on this subject?
 ► In the DEFER trial, the safety of deferring percutaneous 
coronary intervention (PCI) based on fractional flow 
reserve (FFR) was established with a FFR cut- off value 
of >0.75. In the FAME trials, improved clinical outcomes 
were demonstrated if PCI was performed in all lesions 
with FFR≤0.80. Previous studies suggest that 20%–25% 
of patients undergoing FFR assessment have values that 
fall within the grey zone of 0.75–0.80. There is conflicting 
evidence regarding the benefits of PCI in these patients and 
no data from randomised clinical trials.
What might this study add?
 ► In patients with grey- zone FFR values randomised to either 
medical therapy or PCI plus medical therapy, those treated 
by PCI had less angina and improved quality of life. Some of 
this benefit could be due to placebo as this trial had no sham 
control.
 ► Only 17% of these patients had evidence of significant 
ischaemia based on stress myocardial perfusion studies using 
MRI.
 ► Only 8% of these patients had evidence of significant 
ischaemia based on hyperaemic stenosis resistance, an 
invasive physiological index derived from both pressure and 
Doppler flow measurements.
how might this impact on clinical practice?
 ► Clinicians considering PCI in stenoses with grey- zone FFR 
values should understand that there is a low incidence of 
significant myocardial ischaemia in this group. Nevertheless, 
patients can be advised that there is a reasonable probability 
of symptomatic improvement, albeit that some of this could 
be a placebo effect.
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